Probiotics + mesalazine improved microflora composition in IBD patients, increased count of Bifidobacterium and Lactobacillus, and reduced levels of IL-6, C-reactive protein, lactoferrin, α-1-antitrypsin, and β-2 microglobulin. This evidence concerns the gene CRP and inflammatory bowel disease.